Biomarker Panel for Cognitive Impairment Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Alzheimer's disease are inadequate for early detection and differentiation, particularly in the prodromal stages, due to lack of sensitive and reproducible biomarkers, leading to delayed diagnosis and ineffective therapeutic interventions.
Innovation Solution
An in vitro or ex vivo method utilizing a panel of biomarkers such as MCSF, IL-3, CCL18, CCL15, CD3, CD11c, CCR2, and RANTES in peripheral blood mononuclear cells to assess cognitive function, enabling the identification of Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI), and early or late MCI, as well as predicting disease progression and treatment responsiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for Alzheimer's disease, then diagnosis can be made, but early detection and differentiation in prodromal stages is inadequate
Solution Approach 1:
The patent segments the diagnostic process by identifying distinct biomarker profiles for different cognitive impairment stages (SCI, eMCI, lMCI, AD). This segmentation enables precise differentiation between prodromal stages that were previously indistinguishable, allowing early detection before full-blown Alzheimer's disease develops.
Solution Approach 2:
The patent performs preliminary diagnostic action by detecting biomarker changes in prodromal stages (SCI and MCI) before full Alzheimer's disease manifests. This preliminary detection enables early intervention opportunities that were previously unavailable, addressing the diagnosis delay problem.
2Measurement precision
If a panel of multiple biomarkers is evaluated, then cognitive impairment stages can be accurately stratified, but diagnostic complexity increases
Solution Approach 1:
The patent segments the biomarker panel into functionally distinct groups: inflammatory markers (MCSF, IL-3, CCL18, CCL15, RANTES), cellular markers (CD3, CD11c), and chemokine receptors (CCR2). This segmentation allows systematic evaluation of multiple biomarkers while maintaining diagnostic clarity through organized interpretation of each marker's specific contribution to stage differentiation.
3Loss of time
If biomarker evaluation is performed in prodromal stages, then early detection is enabled, but lack of sensitive biomarkers previously prevented accurate diagnosis
Solution Approach 1:
The patent creates a composite diagnostic approach by combining multiple biomarkers (MCSF, IL-3, CCL18, CCL15, RANTES, CD3, CD11c, CCR2) into an integrated diagnostic profile. This composite methodology provides the sensitivity needed for prodromal stage detection, where individual biomarkers alone would be insufficient, enabling early detection with high measurement precision.
Data Source
AI summary
The invention relates to in vitro or ex vivo methods for assessing the cognitive function of a subject in the context of the prevention of neurodegenerative diseases. A particular method comprises a step of associating a subject to a cognitive status selected from healthy cognitive status, Subjective Cognitive Impairment, Mild Cognitive Impairment and neurodegenerative disease, and the association of cognitive status results from the evaluation of glycosylated MCSF and CCR2 expressed at the surface of PBMC in a biological sample from the subject. The present invention also provides kits suitable for implementing such methods.